cp wire

CP Wire Articles

  • OMS721 is also being studied in atypical hemolytic uremic syndrome, IgA nephropathy, and lupus nephritis
  • The drug also has orphan status for the treatment of primary IgA nephropathy... read more
Tue, 08/28/18 - 11:53 am
CP Staff



Reflection Biotechnologies Limited ("ReflectionBio") announced on 8/28/18 that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ReflectionBio's RBIO-101... read more

Tue, 08/28/18 - 09:20 am
CP Staff
  • The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy than would be expected with LDAC alone... read more

Mon, 08/27/18 - 09:49 am
CP Staff


Magnolia Neurosciences Corporation (Magnolia) announced on 8/27/18 that Korysso Therapeutics, Inc. (DBA: Magnolia Tejas Corporation), the company’s wholly owned, Houston-based subsidiary, has... read more

Mon, 08/27/18 - 09:22 am
CP Staff

LifeMax Laboratories, Inc. (“LifeMax”) announced on 8/27/18 an exclusive worldwide license from Novartis Pharma AG for the right to develop, manufacture and commercialize BPR277, a clinical stage... read more

Mon, 08/27/18 - 09:12 am
CP Staff

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced on 8/24/18 that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ADVM-053, a... read more

Fri, 08/24/18 - 09:50 am
CP Staff
  • Liver cancer is the second leading cause of cancer-related deaths
  • Treatment options for this type of liver cancer are limited
  • Lenvima is also approved in the US as first-... read more
Thu, 08/23/18 - 10:09 am
CP Staff
  • Proceeds will be used to launch Jornay PM
  • Jornay PM is a novel formulation of methylphenidate which is taken in the evening
  • Trials demonstrated improvement in the severity... read more
Thu, 08/23/18 - 09:47 am
CP Staff

The U.S. Food and Drug Administration announced on 8/22/18 that it has approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the... read more

Wed, 08/22/18 - 11:36 pm
CP Staff

Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries that drive functions of the microbiome organ, today... read more

Wed, 08/22/18 - 09:29 am
CP Staff
  • There are an esitmated 1 million annual global fibroid procedures
  • The company estimates the annual US market to be more than $1 billion


Gynesonics, a women’s... read more

Wed, 08/22/18 - 09:13 am
CP Staff

SkinBio Therapeutics Provided a Business Update on 8/16/18

Using a third party manufacturer, the company has now achieved significant manufacturing scale up with, with no... read more

Tue, 08/21/18 - 12:30 pm
CP Staff
  • An estimated 250 million women worldwide are affected by urinary incontinence
  • Renovia currently has a product on the market to treat female urinary incontinence
  • The company... read more
Tue, 08/21/18 - 10:13 am
CP Staff
  • New CEO Has 25 Years Experience in the ophthalmic pharmaceutical space
  • Luminate met primary endpoints in Ph IIb study
  • Luminate is a first-in-class integrin peptide therapy... read more
Tue, 08/21/18 - 09:55 am
CP Staff



Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc (Nasdaq: IRWD , “Ironwood”)  announced on 8/21/18 that approval... read more

Tue, 08/21/18 - 09:38 am
CP Staff



Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced on 8/20/18 that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA)... read more

Mon, 08/20/18 - 09:59 am
CP Staff
  • Ph I trial showed reduction in biomarker associated with anti-tumor activity in animal models
  • There were no serious or dose-limiting adverse events in the Ph I trial
  • Aravive... read more
Mon, 08/20/18 - 09:44 am
CP Staff
  • The acquisition supports Novo Nordisk's goal to develop glucose responsive insulins
  • ... read more
Fri, 08/17/18 - 09:52 am
CP Staff
  • Current dry-powder glucagon formulations must be used immediately because they begin to degrade after reconstitution
  • Xeris’ ready-to-use liquid glucagon is room-temperature stable... read more
Fri, 08/17/18 - 09:24 am
CP Staff
  • BioNTech will receive $120 million in upfront, equity and near-term research payments
  • Company is elligible for $305 million in additional payments
  • BioNTech has additional... read more
Thu, 08/16/18 - 10:11 am
CP Staff

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.